Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.
Authors
Blackhall, Fiona HPeters, S
Bubendorf, L
Dafni, U
Kerr, K
Hager, H
Soltermann, A
O'Byrne, K
Dooms, C
Sejda, A
Hernández-Losa, J
Marchetti, A
Savic, S
Tan, Q
Thunnissen, E
Speel, E
Cheney, R
Nonaka, Daisuke
de Jong, J
Martorell, M
Letovanec, I
Rosell, R
Stahel, R
Affiliation
Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, ManchesterIssue Date
2014-07-28
Metadata
Show full item recordAbstract
The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.Citation
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. 2014: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2013.54.5921PubMed ID
25071109Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2013.54.5921
Scopus Count
Collections
Related articles
- Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
- Authors: Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S, European Thoracic Oncology Platform Lungscape Consortium.
- Issue date: 2018 Mar
- Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
- Authors: Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D
- Issue date: 2016 Sep 27
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
- Authors: Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F
- Issue date: 2016 Apr
- Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
- Authors: Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu G, Su D, Li X, Wu S, Chen X, Qin N, Zeng X, Zhang H, Zhang Z, Zhang S
- Issue date: 2014
- Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
- Authors: Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser RS, Blumenkrantz M, Lavoie J, Fortin F, Bojarski A, Côté GB, van den Berghe JA, Rashid-Kolvear F, Trotter M, Sekhon HS, Albadine R, Tran-Thanh D, Gorska I, Knoll JH, Xu J, Blencowe B, Iafrate AJ, Hwang DM, Pintilie M, Gaspo R, Couture C, Tsao MS
- Issue date: 2014 Sep